AI-generated analysis. Always verify with the original filing.
Dermata Therapeutics issued a press release on March 26, 2026, reporting financial results for the year ended December 31, 2025, announcing a strategic pivot to direct-to-consumer skincare products under the Tome brand, and planning launches of Foundational Treatment in mid-2026 and Clearing Treatment shortly after.
Event Type
Disclosure
Mandatory
Variant
8-K
and Exhibit 99.1 hereto shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any g
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated March 26, 2026, issued by Dermata Therapeutics, Inc. entitled
| Metric | Value | Basis |
|---|---|---|
| Research and Development Expenses | $2.9K | GAAP |
| Selling, General and Administrative Expenses | $4.8K | GAAP |
| Loss from Operations | $-7.8K | GAAP |
| Net Loss | $-7.6K | GAAP |
| Net Loss per Common Share, Basic and Diluted | $-8.16 | GAAP |
Kyra Peckaitis
Effective: 2026-03